Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients

Mirati Therapeutics has reported that Krazati demonstrated durable efficacy in a two-year follow-up from a Phase I/Ib and Phase II trial for patients with non-small cell lung cancer (NSCLC).